Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CDC42 | P60953 | 1/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154899 | 0.89 | ABCB11 (0.69) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL14349888 | 0.88 | ABCB11 (0.67) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL17761206 | 0.86 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL12836544 | 0.86 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL988779 | 0.86 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL15782118 | 0.86 | AKR1C3 (0.62) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL2207966 | 0.85 | FFAR1 (0.56) | TSHRFFAR1L3MBTL1 | |
| SCHEMBL9696473 | 0.84 | AKR1C3 (0.60) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL11155802 | 0.84 | ABCB11 (0.61) | ABCB11AKR1C3AKR1C2PTGS1PTGS2 | |
| SCHEMBL12191890 | 0.83 | L3MBTL1 (0.57) | LMNAFFAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55055136-A | — | — | None | — | — | JP | disclosed |
| US-20180028478-A1 | ANTIVIRAL COMPOSITIONS DIRECTED AGAINST THE NUCLEOPROTEIN OF INFLUENZA VIRUSES | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2018-02-01 | — | — | US | disclosed |
| US-9783482-B2 | Antiviral compositions directed against the influenza virus nucleoprotein | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20140163107-A1 | ANTIVIRAL COMPOSITIONS DIRECTED AGAINST THE INFLUENZA VIRUS NUCLEOPROTEIN | INSTITUT NATIONAL DE LA RECHERCHE AGRONIMIQUE (FR) | 2014-06-12 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2065047-A1 | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | Board of Regents, The University of Texas System (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1214940-B1 | Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein | UNIV TEXAS (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008051403-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| EP-1214940-A1 | Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-0805684-B1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | UNIV TEXAS (US) | 2002-06-12 | — | — | EP | disclosed |
| US-5955451-A | NONSTEROID ANTIINFLAMMATORY AGENTS COMPLEXED WITH ZWITTERIONS OR PHOSPHOLIPIDS FOR NONIRRITATION OF GASTROINTESTINAL SYSTEMS AND ANTIPYRETICS | THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS | 1999-09-21 | — | — | US | disclosed |
| WO-1998013073-A9 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | — | 1998-08-06 | — | — | WO | disclosed |
| US-5763422-A | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998013073-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5032588-A | Non-steroidal antiinflammatory | ABBOTT LABORATORIES (US) | 1991-07-16 | — | — | US | disclosed |
| WO-1991008744-A1 | THIAZOLE LIPOXYGENASE-INHIBITING COMPOUNDS DERIVED FROM NON-STEROIDAL ANTIINFLAMMATORY CARBOXYLIC ACIDS | ABBOTT LABORATORIES (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4420639-A | Aromatic compounds | BEECHAM GROUP LIMITED (GB) | 1983-12-13 | — | — | US | disclosed |
| JP-S5555136-A | RECEMIZATION OF D- AND L-2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID MIXTURE | GRELAN PHARMACEUT CO LTD | 1980-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028478-A1 | ANTIVIRAL COMPOSITIONS DIRECTED AGAINST THE NUCLEOPROTEIN OF INFLUENZA VIRUSES | SNRPE, HNRNPA1, ADAR | ABCB11 4629/4885AKR1C3 4143/4885AKR1C2 4411/4885 |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | ABCB11 198/4885AKR1C3 103/4885AKR1C2 105/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | ABCB11 525/4885AKR1C3 239/4885AKR1C2 297/4885 |
| US-20140163107-A1 | ANTIVIRAL COMPOSITIONS DIRECTED AGAINST THE INFLUENZA VIRUS NUCLEOPROTEIN | SNRPE, HNRNPA1, SNRPF | ABCB11 4779/4885AKR1C3 4421/4885AKR1C2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.